{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:44:16Z","timestamp":1769204656601,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.vaccine.2016.02.060","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T19:09:33Z","timestamp":1457032173000},"page":"2015-2020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Do selective immunisation against tuberculosis and hepatitis B reach the targeted populations? A nationwide register-based study evaluating the recommendations in the Norwegian Childhood Immunisation Programme"],"prefix":"10.1016","volume":"34","author":[{"given":"Berit","family":"Feiring","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida","family":"Laake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tor","family":"Molden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siri E.","family":"H\u00e5berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2332-2443","authenticated-orcid":false,"given":"Hanne","family":"N\u00f8kleby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siri Sch\u00f8yen","family":"Seterelv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Magnus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lill","family":"Trogstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.02.060_bib0170","series-title":"Global Tuberculosis Report, 2015","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0175","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0180","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0185","first-page":"27","article-title":"BCG vaccine. WHO position paper","volume":"79","author":"World Health Organization","year":"2004","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0962-8479(94)90003-5","article-title":"Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease","volume":"75","year":"1994","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0195","series-title":"Utredning om bruk av BCG-vaksine i Norge [Assessment on the use of BCG vaccine in Norway]","author":"Norwegian Institute of Public Health","year":"2008"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0200","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/thoraxjnl-2013-203931","article-title":"Uptake of neonatal BCG vaccination in England: performance of the current policy recommendations","volume":"69","author":"Nguipdop-Djomo","year":"2014","journal-title":"Thorax"},{"issue":"37","key":"10.1016\/j.vaccine.2016.02.060_bib0205","article-title":"Recent changes in tuberculosis control and BCG vaccination policy in France","volume":"12","author":"Bruhl","year":"2007","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2807\/esm.11.03.00607-en","article-title":"BCG in Finland: changing from a universal to a selected programme","volume":"11","author":"Salo","year":"2006","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0215","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1183\/09031936.00113413","article-title":"Bacille Calmette-Guerin vaccination: the current situation in Europe","volume":"43","author":"Dara","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0220","first-page":"405","article-title":"Hepatitis B vaccines. WHO position paper","volume":"84","author":"World Health Organization","year":"2009","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0225","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1473-3099(07)70136-6","article-title":"Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe?","volume":"7","author":"Zuckerman","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0230","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1473-3099(08)70003-3","article-title":"Universal hepatitis B vaccination","volume":"8","author":"Kretzschmar","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0235","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1473-3099(08)70004-5","article-title":"Universal hepatitis B vaccination","volume":"8","author":"Hahne","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0240","doi-asserted-by":"crossref","first-page":"f4057","DOI":"10.1136\/bmj.f4057","article-title":"Should Europe have a universal hepatitis B vaccination programme?","volume":"347","author":"Van Damme","year":"2013","journal-title":"BMJ"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2016.02.060_bib0245","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12535","article-title":"A cohesive European policy for hepatitis B vaccination, are we there yet?","volume":"20","author":"Lernout","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0250","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.jhep.2015.01.018","article-title":"Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs","volume":"62","author":"Locarnini","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0255","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.1016\/j.vaccine.2011.09.042","article-title":"Preparing for the next public debate: universal vaccination against hepatitis B","volume":"29","author":"Houweling","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2016.02.060_bib0260","doi-asserted-by":"crossref","DOI":"10.2807\/ese.16.12.19824-en","article-title":"vaccination coverage and incidence of paediatric tuberculosis following two major changes in BCG vaccination policy in France","volume":"16","author":"Guthmann","year":"2011","journal-title":"Euro Surveill"},{"issue":"16","key":"10.1016\/j.vaccine.2016.02.060_bib0265","doi-asserted-by":"crossref","DOI":"10.2807\/ese.17.16.20147-en","article-title":"The Norwegian immunisation register \u2013 SYSVAK","volume":"17","author":"Trogstad","year":"2012","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0270","series-title":"Vaksinasjonsboka-veileder om vaksinasjon [Guidance on vaccination]","author":"Norwegian Institute of Public Health","year":"2015"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0275","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2105\/AJPH.2011.300239","article-title":"Effectiveness of the targeted hepatitis B vaccination program in Greenland","volume":"102","author":"Borresen","year":"2012","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0280","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/jech.2009.092288","article-title":"Effectiveness and impact of hepatitis B virus vaccination of children with at least one parent born in a hepatitis B virus endemic country: an early assessment","volume":"64","author":"Hontelez","year":"2010","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0285","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2807\/esm.11.03.00606-en","article-title":"Selective BCG vaccination in a country with low incidence of tuberculosis","volume":"11","author":"Romanus","year":"2006","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0290","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1016\/j.vaccine.2011.05.020","article-title":"Barriers to implementation of the new targeted BCG vaccination in France: a cross sectional study","volume":"29","author":"Rossignol","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0295","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1471-2334-7-82","article-title":"Knowledge and attitudes of parents and professionals to neonatal BCG vaccination in light of recent UK policy changes: a questionnaire study","volume":"7","author":"Gordon","year":"2007","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0300","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.vaccine.2009.10.128","article-title":"Parental attitude towards childhood HBV vaccination in The Netherlands","volume":"28","author":"Hontelez","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0305","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/thx.2004.036269","article-title":"Ethnic differences in selective neonatal BCG immunisation: white British children miss out","volume":"61","author":"Srinivasan","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0310","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0962-8479(92)90149-E","article-title":"The impact of changing BCG coverage on tuberculosis incidence in Swedish-born children between 1969 and 1989","volume":"73","author":"Romanus","year":"1992","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0315","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.arcped.2009.01.006","article-title":"BCG vaccine coverage in private medical practice: First data in children below two years old, seven months after the end of compulsory vaccination in France","volume":"16","author":"Guthmann","year":"2009","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0320","series-title":"Barnevaksinasjonsprogrammet i Norge. Rapport for perioden 2001\u20132010. [The Norwegian Childhood Immunisation Programme. Report for the period 2001\u20132010.]","author":"Feiring","year":"2012"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0325","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1016\/j.vaccine.2010.04.037","article-title":"Hepatitis B immunisation programmes in European Union, Norway and Iceland: where we were in 2009?","volume":"28","author":"Mereckiene","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.060_bib0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0264-410X(02)00440-1","article-title":"Hepatitis B vaccination: how to reach risk groups","volume":"21","author":"Francois","year":"2002","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16002553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16002553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T15:53:03Z","timestamp":1654530783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16002553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":33,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0264410X16002553"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.02.060","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do selective immunisation against tuberculosis and hepatitis B reach the targeted populations? A nationwide register-based study evaluating the recommendations in the Norwegian Childhood Immunisation Programme","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.02.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}